single isomer drugs

Tweet

Single Isomer Drugs: The total value of enantiomerically pur drugs continues to grow rapidly. Their share is around 25% of total world wide pharmaceutical sales. Single isomer drug sales are expected to cross USS150 billion by 2005 with an annual growth rate of 7 to 8% per annum during 2000-05. The largest sales categories for single isomer products are cardiovascular, central nervous system and anti-cancer drugs, antibiotics, hormones and vaccines. There are already more than 15 racemic drugs with potential racemic switches which could successfully manage significant market exclusivity extension. Globally, fine chemical and pharmaceutical companies have been developing technologies for single isomer drugs since they have viewed this option as a potent method to extend patent life and also to obtain new therapeutic properties if such a scope exists